Chen Peixin, Kuang Peng, Wang Lei, Li Wei, Chen Bin, Liu Yu, Wang Hao, Zhao Sha, Ye Lingyun, Yu Feng, He Yayi, Zhou Caicun
Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China.
Department of Medical School, Tongji University, Shanghai, China.
Transl Lung Cancer Res. 2020 Jun;9(3):768-786. doi: 10.21037/tlcr-19-547.
Small-cell lung cancer (SCLC), the highest malignant cancer amongst different types of lung cancer, has the feature of lower differentiation, rapid growth, and poor survival rate. Despite the dramatically initial sensitivity of SCLC to various types of treatment methods, including chemotherapy, radiotherapy and immunotherapy, the emergence of drugs-resistance is still a grandly clinical challenge. Therefore, in order to improve the prognosis and develop new therapeutic approaches, having a better understanding of the complex mechanisms of resistance in SCLC is of great clinical significance. This review summarized recent advances in understanding of multiple mechanisms which are involved in the resistance during SCLC treatment, including DNA-related process, RNA-related process, apoptosis-related mechanism, and the process of drug accumulation and metabolism.
小细胞肺癌（SCLC）是不同类型肺癌中恶性程度最高的癌症，具有分化程度低、生长迅速和生存率低的特点。尽管SCLC对包括化疗、放疗和免疫治疗在内的各种治疗方法最初具有显著的敏感性，但耐药性的出现仍然是一个重大的临床挑战。因此，为了改善预后并开发新的治疗方法，更好地了解SCLC耐药的复杂机制具有重要的临床意义。本综述总结了近年来对SCLC治疗过程中耐药相关多种机制的理解进展，包括与DNA相关的过程、与RNA相关的过程、凋亡相关机制以及药物积累和代谢过程。
